Pacira BioSciences (PCRX) Net Cash Flow (2010 - 2026)

Pacira BioSciences' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$14.3 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 308.85% year-over-year to -$14.3 million; the TTM figure through Mar 2026 stood at -$139.3 million (down 239.88% YoY), while the FY2025 annual figure was -$118.2 million, down 195.69% from the prior year.
• Net Cash Flow was -$14.3 million for Q1 2026 at Pacira BioSciences, down from $11.4 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $63.0 million in Q2 2024 to a low of -$358.8 million in Q1 2022.
• Historically, Net Cash Flow has averaged -$26.0 million across 5 years, with a median of $6.8 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow jumped 1125.15% in 2023, then sank 13965.07% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$5.3 million in 2022, then surged by 1125.15% to $54.2 million in 2023, then plunged by 43.13% to $30.8 million in 2024, then tumbled by 63.1% to $11.4 million in 2025, then slumped by 225.57% to -$14.3 million in 2026.
• The last three Net Cash Flow figures came in at -$14.3 million (Q1 2026), $11.4 million (Q4 2025), and -$153.0 million (Q3 2025), per Business Quant data.